Loading
A phase 1/2 trial of Pembrolizumab, Trastuzumab, Trastuzumab emtansine in ovarian cancer and melanoma, run by Ascendis Pharma Oncology Division A/S, active and no longer recruiting.
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies is a phase 1/2 interventional study registered as NCT05081609 by Ascendis Pharma Oncology Division A/S, with 320 participants enrolled, started 2022-01-11 and due to reach its primary completion in 2027-08. Interventions recorded: TransCon IL-2 β/γ, Pembrolizumab, Chemotherapy drug, TransCon TLR7/8 Agonist, Surgery. Conditions listed: Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Platinum-resistant Ovarian Cancer. No results are recorded here; the registry entry is the source.
Shares Trastuzumab emtansine, Trastuzumab, Immune checkpoint inhibitors.
Shares Trastuzumab, Pembrolizumab, Immune checkpoint inhibitors.
Shares Trastuzumab, Pembrolizumab, Immune checkpoint inhibitors.
Shares Trastuzumab emtansine, Trastuzumab.
Shares Trastuzumab emtansine, Trastuzumab.
Shares Trastuzumab, Pembrolizumab, Immune checkpoint inhibitors.
Shares Trastuzumab, Pembrolizumab.
Shares Trastuzumab, Pembrolizumab, Immune checkpoint inhibitors.